BMS at ASCO and EHA 2021

Driving progress and novel approaches to improve survival in cancer and blood disorders

Intended for U.S. scientific audiences only.

Our data at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings highlights our diverse pipeline and demonstrates advancements in immunotherapy, cell therapy and protein degradation. As we make progress in improving survival outcomes for patients with cancer and addressing the unmet needs of patients with difficult-to-treat diseases and blood disorders, we also recognize that the needs of patients extend beyond treatment. 

Driving Innovation for All Patients 

Hear from our CEO, Giovanni Caforio, M.D., about our commitment to helping patients with cancer and blood disorders live better, longer and healthier lives.   

Our Data at ASCO and EHA 

Read more about our key data being presented at ASCO and EHA.

Learn more about BMS’ data presentations at EHA 2021 
Check out the BMS ASCO Virtual Exhibit

Enabling Durable Long-Term Survival & Addressing Cancers with High Unmet Needs

Our innovative cancer medicines have had a dramatic impact on disease outcomes, making long-term survival a possibility for more patients. But there is more work to do.

Kald Abdallah, Driven by a Personal Passion, Wants to Discover Ways to Treat Cancer Earlier >

Learn more about the personal passion that drives Kald Abdallah, M.D., Ph. D., our senior vice president and head, Worldwide Medical Oncology, to continue exploring the use of immunotherapy in earlier stages of cancer. 

Cell Therapy  >

Learn more about the science behind cell therapy. 

Approaching Thoracic Cancers from Different Angles >

The needs of patients with lung cancer are unique, which is why we’re exploring a variety of treatment approaches. Learn from our vice president and Head of Oncology Clinical Development, Sabine Maier, M.D.

Advancing Acute Myeloid Leukemia Research through Epigenetics >

Instead of killing the cell, hypomethylating agents, or HMAs, alter the signaling process by re-expressing genes to work properly again. Learn more about the treatment of AML through epigenetics. 

Addressing Cancer Earlier  >

Learn more from Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, about how we're investigating immunotherapies in earlier stages of cancer and in more tumor types to maximize the impact for patients.

Introducing the Next Wave of Therapies

Our research is propelled by our rich history of developing life-changing medicines and our unwavering commitment to follow the science and push forward when it matters most.

Protein Degradation with Molecular Glue

Learn about protein degradation using “molecular glues” as an approach to treat diseases with significant unmet needs.

Explore our Comprehensive Approach to Cancer Research >

Learn how our comprehensive pipeline, spanning multiple approaches across platforms and modalities, sets us apart and enables us to fulfill our vision of transforming patients’ lives through science. 

Learn more about the expanding global prevalence of beta-thalassemia and increasing needs of patients navigating an inherited blood disorder during the COVID-19 pandemic.

Understanding the Potential of LAG-3

Learn more about lymphocyte-activation gene 3 (LAG-3), its significance in cancer and how researchers are finding approaches to optimize the LAG-3 blockade.

Advancing Cancer Research: Yesterday, Today and Tomorrow  >

Explore milestones that have shaped cancer discovery, and how researchers are using these learnings to advance science today.

Confronting the Complexities of Cancer >

Learn about our comprehensive approach to cancer research across the biological spectrum, exploring various modalities, research approaches and important areas of focus.  

Taking a Comprehensive Approach to Treat the Biology of Cancer >

Learn how BMS is pursuing multiple approaches to match the biology of cancer and advance the next generation of treatments. 

Supporting All Patients with Cancers and Blood Disorders

We are committed to supporting all cancer patients at each stage of their journey. Learn more about our efforts to accelerate and expand health equity and improve survivorship care for patients.

Addressing All Aspects of Cancer Care

What does progress in cancer mean to you? A patient and leaders at BMS share their perspectives on how we can continue to improve the lives of patients with cancer.

Committed to Supporting All Cancer Patients at Each Stage of Their Journey >

Learn more about our support of ASCO’s first-ever scientific track dedicated to research on health disparities, new research on the experience of LGBTQI+ cancer survivors and an important discussion about veterans’ health.

Health Equity Q&A: The Gaps in Cancer Care  >

Join our panel discussion on health equity and survivorship to explore access issues, disparities and cultural barriers faced by cancer survivors.

Partnering to Improve Cancer Care in the Age of COVID-19 >

Leaders from BMS and the oncology advocacy community discuss the immediate and long-term impacts for cancer patients as a result of the COVID-19 pandemic.

Accelerating and Expanding Health Equity and Diversity Efforts >

See how we’re working to address health disparities to serve more patients with serious disease. 

Too Often, African American Patients with Multiple Myeloma Aren't Getting the Best Care Possible >

How the Standing in the Gaap program aims to narrow the gap in health disparities for multiple myeloma.

Resources

Our research at ASCO and EHA spans several types of cancer and blood disorders. Learn more about some of them below.

LAG-3 Infographic

Learn about the LAG-3 immune checkpoint inhibitor.

Protein Degradation Fact Sheet

Understand the process of cellular protein degradation.

Disease State Infographics

 

Download infographic resources on different cancers and disease types.